CASI Latest News, Press Relases and Analysis

All

Press Releases

4 days ago - By: ACCESS Newswire

CASI Pharmaceuticals to Participate at Guggenheim Healthcare Innovation Conference

5 days ago - By: ACCESS Newswire

CASI Pharmaceuticals Announces Upcoming Presentation of Clinical Results for CID-103 at the 67th American Society of Hematology (ASH) Annual Meeting

25 days ago - By: Benzinga - Mentions: PTIX TLPH GLMD NDRA ...

12 Health Care Stocks Moving In Monday's After-Market Session

a month ago - By: Benzinga - Mentions: SNGX SSKN CRNX APLT ...

12 Health Care Stocks Moving In Friday's Intraday Session

a month ago - By: ACCESS Newswire

CASI Pharmaceuticals Appoints James Huang to Board of Directors

2 months ago - By: ACCESS Newswire

CASI Pharmaceuticals Announces Safety Monitoring Committee Recommendation to Escalate CID-103 Dose to Next Cohort in Phase 1 Immune Thrombocytopenia (ITP) Study

2 months ago - By: ACCESS Newswire

CASI Pharmaceuticals Appoints Barbara Krebs-Pohl, PhD to Board of Directors

3 months ago - By: ACCESS Newswire

CASI Pharmaceuticals Announces FDA Clearance of IND Application for CID-103 in Renal Allograft Antibody-Mediated Rejection (AMR)

2 months ago - By: ACCESS Newswire

CASI Pharmaceuticals to Present at H.C. Wainwright 27th Annual Global Investment Conference

2 months ago - By: ACCESS Newswire

CASI Pharmaceuticals Announces Second Quarter 2025 Business and Financial Results

2 months ago - By: ACCESS Newswire

CASI Pharmaceuticals to Participate at Cantor Global Healthcare Conference 2025

2 months ago - By: Zacks Investment Research - Mentions: VEEV

Veeva Systems (VEEV) Surpasses Q2 Earnings and Revenue Estimates

3 months ago - By: Zacks Investment Research - Mentions: VYNE

VYNE Therapeutics Inc. (VYNE) Reports Q2 Loss, Lags Revenue Estimates

3 months ago - By: Zacks Investment Research - Mentions: VXRT

VAXART, INC. (VXRT) Reports Q2 Loss, Beats Revenue Estimates

3 months ago - By: Zacks Investment Research - Mentions: XBIO

Xenetic Biosciences (XBIO) Reports Q2 Loss, Misses Revenue Estimates

3 months ago - By: Zacks Investment Research - Mentions: CRNX

Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q2 Loss, Lags Revenue Estimates

3 months ago - By: Zacks Investment Research - Mentions: BVS

Bioventus (BVS) Misses Q2 Earnings and Revenue Estimates

4 months ago - By: ACCESS Newswire

CASI Pharmaceuticals Appoints David Cory as Chief Executive Officer to Lead U.S. Company Focused on Clinical Development of CID-103, a Potential Best in Class Anti-CD38 Program

6 months ago - By: ACCESS Newswire

CASI Pharmaceuticals Provides Business and Clinical Update

6 months ago - By: ACCESS Newswire

CASI Pharmaceuticals Announces First Quarter 2025 Business and Financial Results

6 months ago - By: Zacks Investment Research - Mentions: AQST

Aquestive Therapeutics (AQST) Reports Q1 Loss, Lags Revenue Estimates

6 months ago - By: ACCESS Newswire

CASI Pharmaceuticals Enters Into Definitive Agreement for the Divestiture of Assets in China

6 months ago - By: ACCESS Newswire

CASI Pharmaceuticals Receives Nasdaq Deficiency Notice Regarding Minimum Market Value Requirement

7 months ago - By: Stocktwits - Mentions: GM

CASI Pharma Stock Rises On $20M Buyout Offer From CEO For China Business Operations: Retail Remains Extremely Bullish

7 months ago - By: ACCESS Newswire

CASI PHARMACEUTICALS INC (CASI) Stock News

CASI Latest News, Press Relases and Analysis

CASI Pharmaceuticals to Participate at Guggenheim Healthcare Innovation Conference

CASI Pharmaceuticals Announces Upcoming Presentation of Clinical Results for CID-103 at the 67th American Society of Hematology (ASH) Annual Meeting

12 Health Care Stocks Moving In Monday's After-Market Session

12 Health Care Stocks Moving In Friday's Intraday Session

CASI Pharmaceuticals Appoints James Huang to Board of Directors

CASI Pharmaceuticals Announces Safety Monitoring Committee Recommendation to Escalate CID-103 Dose to Next Cohort in Phase 1 Immune Thrombocytopenia (ITP) Study

CASI Pharmaceuticals Appoints Barbara Krebs-Pohl, PhD to Board of Directors

CASI Pharmaceuticals Announces FDA Clearance of IND Application for CID-103 in Renal Allograft Antibody-Mediated Rejection (AMR)

CASI Pharmaceuticals to Present at H.C. Wainwright 27th Annual Global Investment Conference

CASI Pharmaceuticals Announces Second Quarter 2025 Business and Financial Results

CASI Pharmaceuticals to Participate at Cantor Global Healthcare Conference 2025

Veeva Systems (VEEV) Surpasses Q2 Earnings and Revenue Estimates

VYNE Therapeutics Inc. (VYNE) Reports Q2 Loss, Lags Revenue Estimates

VAXART, INC. (VXRT) Reports Q2 Loss, Beats Revenue Estimates

Xenetic Biosciences (XBIO) Reports Q2 Loss, Misses Revenue Estimates

Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q2 Loss, Lags Revenue Estimates

Bioventus (BVS) Misses Q2 Earnings and Revenue Estimates

CASI Pharmaceuticals Appoints David Cory as Chief Executive Officer to Lead U.S. Company Focused on Clinical Development of CID-103, a Potential Best in Class Anti-CD38 Program

CASI Pharmaceuticals Provides Business and Clinical Update

CASI Pharmaceuticals Announces First Quarter 2025 Business and Financial Results

Aquestive Therapeutics (AQST) Reports Q1 Loss, Lags Revenue Estimates

CASI Pharmaceuticals Enters Into Definitive Agreement for the Divestiture of Assets in China

CASI Pharmaceuticals Receives Nasdaq Deficiency Notice Regarding Minimum Market Value Requirement

CASI Pharma Stock Rises On $20M Buyout Offer From CEO For China Business Operations: Retail Remains Extremely Bullish

CASI Pharmaceuticals Announces Receipt of An Updated Non-Binding Proposal to Acquire Entire China Business of the Company